Advertisement

Topics

Biosimilars Struggle to Substitute Brand-Name Drugs

08:24 EDT 16 Aug 2017 | Labiotech.eu

Despite bringing a significant price reduction, biosimilars might lag in taking over the market of the drugs they copy because of exclusivity policies set up by the owners of brand-name drugs.  A report in Bloomberg Markets yesterday highlights the case of Inflectra, a biosimilar from ...

This awesome article Biosimilars Struggle to Substitute Brand-Name Drugs appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Biosimilars Struggle to Substitute Brand-Name Drugs

NEXT ARTICLE

More From BioPortfolio on "Biosimilars Struggle to Substitute Brand-Name Drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...